Rxivist combines preprints from bioRxiv with data from Twitter to help you find the papers being discussed in your field. Currently indexing 63,112 bioRxiv papers from 279,939 authors.
Immunotherapy prevents long-term disability in relapsing multiple sclerosis over 15 years
Eva Kubala Havrdova,
Anneke van der Walt,
Vincent Van Pesch,
Maria Laura Saladino,
Jose Luis Sanchez-Menoyo,
on behalf of the MSBase Study group
Posted 23 Aug 2019
bioRxiv DOI: 10.1101/735662
Posted 23 Aug 2019
Objective: Whether immunotherapy improves long-term disability in multiple sclerosis has not been satisfactorily demonstrated. This study examined the effect of immunotherapy on long-term disability outcomes in relapsing-remitting multiple sclerosis. Methods: We studied patients from MSBase followed for 1 year, with 3 visits, 1 visit per year and exposed to a multiple sclerosis therapy, and a subset of patients with 15-year follow-up. Marginal structural models were used to compare the hazard of 12-month confirmed increase and decrease in disability, EDSS step 6 and the incidence of relapses between treated and untreated periods. Marginal structural models were continuously re-adjusted for patient age, sex, pregnancy, date, disease course, time from first symptom, prior relapse history, disability and MRI activity. Results: 14,717 patients were studied. During the treated periods, patients were less likely to experience relapses (hazard ratio 0.60, 95% confidence interval 0.43- 0.82, p=0.0016), worsening of disability (0.56, 0.38-0.82, p=0.0026) and progress to EDSS step 6 (0.33, 0.19-0.59, p=0.00019). Among 1085 patients with 15-year follow-up, the treated patients were less likely to experience relapses (0.59, 0.50- 0.70, p=10-9) and worsening of disability (0.81, 0.67-0.99, p=0.043). Conclusions: Continued treatment with multiple sclerosis immunotherapies reduces disability accrual (by 19-44%), the risk of need of a walking aid by 67% and the frequency of relapses (by 40-41%) over 15 years. A proof of long-term effect of immunomodulation on disability outcomes is the key to establishing its disease modifying properties.
- Downloaded 110 times
- Download rankings, all-time:
- Site-wide: 56,074 out of 63,112
- In neuroscience: 9,926 out of 11,288
- Year to date:
- Site-wide: 37,732 out of 63,112
- Since beginning of last month:
- Site-wide: 19,855 out of 63,112
Downloads over time
Distribution of downloads per paper, site-wide
- Top preprints of 2018
- Paper search
- Author leaderboards
- Overall metrics
- The API
- Email newsletter
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!